This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Hypertonic Saline Dextran in Pediatric Cardiac Surgery

This study has been completed.
Information provided by:
Oslo University Hospital Identifier:
First received: September 13, 2005
Last updated: June 30, 2011
Last verified: January 2008
The purpose of this study is to determine whether infusion of hypertonic saline dextran attenuates the inflammatory response and the water overload, during and after major cardiac surgery in small children.

Condition Intervention Phase
Heart Defects, Congenital Transposition of Great Vessels Heart Septal Defects, Ventricular Endocardial Cushion Defects Drug: 7.5% NaCl in 6% dextran 70 solution Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: The Use of Hypertonic Saline Dextran in Cardiac Surgery Utilizing Cardio Pulmonary Bypass in Children Less Than 17 Weeks Old.

Resource links provided by NLM:

Further study details as provided by Oslo University Hospital:

Primary Outcome Measures:
  • IL-6 and IL-8 2 hours post CPB
  • Extra vascular lung water 2 and 24 hours post CPB

Secondary Outcome Measures:
  • Fluid balance
  • Weight gain
  • Cardiac output
  • Intrathorasic blood volume
  • Blood pressure during the first 24 hours post CPB

Estimated Enrollment: 14
Study Start Date: June 2003
Study Completion Date: February 2005
Primary Completion Date: December 2004 (Final data collection date for primary outcome measure)
Detailed Description:
After major cardiac surgery in small children, extravasation of fluid due to increased capillary leak has negative effect on haemodynamics and respiration. Inflammation cascades are activated by surgery and the use of cardio pulmonary bypass (CPB). We want to test whether a small infusion of 7.5% NaCl in 6% dextran solution before and after CPB reduces inflammatory activation by measuring the levels of interleukins 6 and 8 (IL-6, IL-8). We also measure extravascular lung water, fluid balance and weight during the first 24 hours post CPB.

Ages Eligible for Study:   up to 16 Weeks   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients with congenital heart defect undergoing surgery using cardio pulmonary bypass (CPB).
  • Age below 17 weeks

Exclusion Criteria:

  • Preoperative: organ failure (other than heart), serum sodium > 155 mmol/l, central venous pressure > 12 mmHg
  • Perioperative: core temperature < 25 ºC on CPB, re-heparinization, re-operation
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00199771

Sponsors and Collaborators
Oslo University Hospital
Principal Investigator: Gunnar Bentsen, MD Oslo University Hospital
  More Information

Responsible Party: Gunnar Bentsen / Consultant, Rikshospitalet-Radiumhospitalet HF Identifier: NCT00199771     History of Changes
Other Study ID Numbers: 2003-HSD
S-01003 (ethics committee)
Study First Received: September 13, 2005
Last Updated: June 30, 2011

Keywords provided by Oslo University Hospital:
Cardiac Surgery
Infant, Newborn
Hypertonic Solutions
Saline Solution, Hypertonic
Capillary leak
Inflammation Mediators

Additional relevant MeSH terms:
Endocardial Cushion Defects
Heart Septal Defects
Congenital Abnormalities
Heart Defects, Congenital
Heart Septal Defects, Ventricular
Transposition of Great Vessels
Cardiovascular Abnormalities
Cardiovascular Diseases
Heart Diseases
Pharmaceutical Solutions
Plasma Substitutes
Blood Substitutes processed this record on September 18, 2017